Cidofovir 375mg/5ml Injection

Cidofovir 375mg/5ml Injection is a potent nucleotide analog antiviral medication designed to combat severe viral infections in immunocompromised patients. Unlike standard nucleoside analogs that require activation by viral enzymes, Cidofovir is a “nucleotide” analog, meaning it mimics the molecular structure of cytosine and is already partially phosphorylated. Once inside the cell, cellular enzymes convert it into its active diphosphate form. This active metabolite acts as a competitive inhibitor of viral DNA polymerase, the enzyme responsible for replicating the virus’s genetic material. It incorporates itself into the growing viral DNA chain, disrupting further synthesis and effectively halting viral replication. This mechanism makes it particularly valuable for treating viruses that have developed resistance to other antivirals like ganciclovir. Discover how this professional pharmaceutical intervention provides the ultimate clinical strategy for managing cytomegalovirus (CMV) retinitis, offering a powerful line of defense to preserve vision in patients with HIV/AIDS.

The 375mg/5ml vial is the standard high-concentration unit (75 mg/mL) used to prepare intravenous infusions. Due to its exceptionally long intracellular half-life, Cidofovir allows for a convenient dosing schedule: typically once a week for the first two weeks (induction), followed by once every two weeks (maintenance). This infrequent dosing is a significant advantage over daily treatments, although the administration process is complex and requires strict adherence to hydration and co-medication protocols to protect the kidneys.

Indications / Uses of Cidofovir 375mg/5ml Injection

Cidofovir 375mg/5ml Injection is commonly prescribed for the specialized management of the following viral condition:

• CMV Retinitis in AIDS: It is indicated for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). It is typically reserved for patients who are intolerant to or have failed other treatments (like ganciclovir or foscarnet).
• Refractory Viral Infections (Off-Label): Clinicians sometimes utilize it for severe cases of Adenovirus, BK virus (in transplant recipients), and drug-resistant Herpes Simplex Virus (HSV), or Poxvirus infections, although these are not FDA-approved indications.

Key Features

• Nucleotide Analog Structure: The primary feature of Cidofovir is that it does not rely on viral enzymes for initial phosphorylation, allowing it to bypass common resistance mechanisms found in CMV strains.
• Long Half-Life: Its active metabolites remain in cells for extended periods, enabling a unique “once-every-two-weeks” maintenance dosing schedule.
• Potent DNA Polymerase Inhibition: It effectively shuts down the replication machinery of a broad spectrum of DNA viruses.
• 375mg Single-Use Vial: The vial size typically covers the dose for an average adult (based on 5 mg/kg), facilitating single-session use.
• Vision Preservation: It is a critical salvage therapy for halting the progression of retinal necrosis in advanced AIDS.

Storage for Cidofovir 375mg/5ml Injection

To preserve the chemical stability and ultimate potency of the active ingredients, Cidofovir 375mg/5ml Injection should be stored at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F to 86°F). Do not refrigerate or freeze, as low temperatures can cause precipitation of the drug. It is vital to keep the vial in its original carton to protect it from light. Admixtures (diluted solutions) should be used within 24 hours if stored under refrigeration. Store the medication in a secure, professional medical environment strictly out of the reach of children.

Important Note on Cidofovir 375mg/5ml Injection

The administration of Cidofovir 375mg/5ml Injection carries a Black Box Warning for Nephrotoxicity. The drug can cause severe, sometimes fatal, kidney damage. To prevent this, it is mandatory to administer Probenecid and intravenous saline hydration with each dose. Probenecid blocks the accumulation of Cidofovir in the kidney tubules, while saline ensures adequate urine flow.

Strict Protocol: Patients must take oral Probenecid 2g three hours before the infusion, and 1g at 2 hours and 8 hours after the infusion ends. One liter of Normal Saline must be infused prior to the drug. Serum creatinine and urine protein must be monitored within 48 hours before each dose.

Neutropenia (low white blood cell count) is another significant risk; frequent blood counts are required. Carcinogenicity/Teratogenicity: Animal studies suggest Cidofovir may cause cancer and birth defects; it is classified as a potential human carcinogen and causes fetal harm (Pregnancy Category C/D equivalent). It should be handled with chemotherapy-grade precautions. By strictly following these professional guidelines and the Probenecid/hydration protocol, healthcare providers can safely maximize the sight-saving benefits of Cidofovir 375mg/5ml Injection.